



News Release

HYDERABAD, INDIA (13 May 2026) -- SUVEN Life Sciences Limited ("Suven") today announced audited financial results for the quarter and year ended 31 Mar 2026. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13 May 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
Revenue	82.98	55.83	26.90	210.45	175.53
R&D and Operational expenses	521.53	1,061.59	452.88	2,916.18	1,724.29
Depreciation and Amortisation	15.83	13.46	13.47	56.14	58.22
Finance cost	1.58	-	-	1.58	0.47
Total expenses	538.93	1,075.05	466.34	2,973.89	1,782.98
Exceptional items (insurance claim received)	-	-	-	-	-
Tax	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	(455.96)	(1,019.22)	(439.45)	(2,763.44)	(1,607.45)
Other comprehensive income	(4.67)	(7.51)	(5.70)	(11.84)	(5.83)
Total comprehensive income	(460.62)	(1,026.73)	(445.15)	(2,775.28)	(1,613.28)
Paid up equity capital	263.72	227.47	218.07	263.72	218.07
Earnings per share of Rs.1 each (EPS)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Achieves 76% Enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. "This milestone reflects continued momentum in the program, completion of patient enrolment by end of calendar 2026 is certain if not earlier and last patient last visit will be in quarter 1, 2027 enabling progression towards database lock and reporting of results potentially in Q2/Q3 - 2027 calendar year.
- SUVN-G3031 (Samelisant) – Initiated Global Phase 3 clinical study for treatment of EDS in Narcolepsy in April 2026.
- SUVN-911 (Ropanicant) – Phase 2B clinical study in USA is complete. Data read out expected soon.
- SUVN-D4010 (Usmarapride) – New IND submission done with FDA for Phase-2 POC (proof of concept) for the "Treatment of cognitive dysfunction in adults with major depressive disorder (MDD) and Phase 2 double blind study will start during calendar 2026.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and now preparing for Phase 2 clinical study.

(d) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 7 patents during the period covering countries ARIPO, EPO, Japan and Mexico.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com